129 related articles for article (PubMed ID: 31214257)
1. Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective.
Johar A; Thevarajah S; Heng A; Chan LC; Ch'ng CC; Mohd Safdar NA; Muniandy P; Taib T; Tan WC; Tey KE
Dermatol Res Pract; 2019; 2019():8923168. PubMed ID: 31214257
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical Eczematous Reaction in a Patient With IL-17 Inhibitor-Treated Psoriasis Vulgaris.
Brazen B; Colon J; Hobbs L; Nousari C
Cureus; 2024 May; 16(5):e60051. PubMed ID: 38854303
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence.
Wu JJ; Merola JF; Feldman SR; Menter A; Lebwohl M
Dermatol Ther (Heidelb); 2020 Jun; 10(3):351-364. PubMed ID: 32242325
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical reaction to IL-17A inhibitor: a case report and literature review.
Ren J; Deng L; Guo S; Liu H
Front Med (Lausanne); 2024; 11():1364127. PubMed ID: 38695018
[TBL] [Abstract][Full Text] [Related]
5. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review.
Girolomoni G; Savage L; Gisondi P; Svensson Å; Mahé E; Augustin M; Puig L
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2171-2185. PubMed ID: 37710078
[TBL] [Abstract][Full Text] [Related]
6. New-Onset, Treatment-Resistant Inflammatory Bowel Disease after Administration of Secukinumab for Plaque Psoriasis: A Case Report and Review of the Existing Literature.
Krikelis M; Papathanasiou E; Leonidakis G; Pardalis P; Michopoulos S; Zampeli E
Mediterr J Rheumatol; 2024 Mar; 35(1):150-155. PubMed ID: 38736963
[TBL] [Abstract][Full Text] [Related]
7. Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: A multi-case report analysis.
Fiorella C
Clin Case Rep; 2022 Jan; 10(1):e05302. PubMed ID: 35127089
[TBL] [Abstract][Full Text] [Related]
8. Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China.
Kuang Y; Li Y; Lv C; Li M; Zhang Z; Chen Y; Chen W; Wang X; Ba L; Zhong Y; Feldman S
Dermatol Ther (Heidelb); 2024 May; 14(5):1245-1257. PubMed ID: 38733512
[TBL] [Abstract][Full Text] [Related]
9. Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond.
Portarapillo A; Potestio L; Tommasino N; Lauletta G; Feo F; Salsano A; Martora F; Caso F; Megna M
Expert Opin Pharmacother; 2024 Jun; ():1-12. PubMed ID: 38916590
[TBL] [Abstract][Full Text] [Related]
10. Systemic Treatment of Pediatric Psoriasis: A Review.
Napolitano M; Megna M; Balato A; Ayala F; Lembo S; Villani A; Balato N
Dermatol Ther (Heidelb); 2016 Jun; 6(2):125-42. PubMed ID: 27085539
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.
Armstrong AW; Vender R; Kircik L
J Clin Aesthet Dermatol; 2016 Jun; 9(6 Suppl 1):S12-S16. PubMed ID: 28439342
[No Abstract] [Full Text] [Related]
12. Clinical Characteristics and Therapeutic Aspects of Blaschko Linear Psoriasis.
Chen L; Cheng Y; Peng L; Jia X; Liu G; Shen Z
Dermatol Ther (Heidelb); 2024 Apr; 14(4):1039-1048. PubMed ID: 38578386
[TBL] [Abstract][Full Text] [Related]
13. A practical approach to monitoring patients on biological agents for the treatment of psoriasis.
Emer JJ; Frankel A; Zeichner JA
J Clin Aesthet Dermatol; 2010 Aug; 3(8):20-6. PubMed ID: 20877538
[TBL] [Abstract][Full Text] [Related]
14. Biologics in Dermatology: Off-Label Indications.
Mitra D; Chopra A; Saraswat N; Mitra B; Talukdar K; Agarwal R
Indian Dermatol Online J; 2020; 11(3):319-327. PubMed ID: 32695686
[TBL] [Abstract][Full Text] [Related]
15. Asymptomatic microscopic colitis induced by secukinumab.
Megna M; De Lucia M; Fornaro L; Tommasino N; Castiglione F; Cacciapuoti S; Testa A
JAAD Case Rep; 2024 Jun; 48():11-13. PubMed ID: 38745828
[No Abstract] [Full Text] [Related]
16. A new light on secukinumab in pediatric psoriasis.
Romita P; Bonamonte D; DE Marco A; Mercurio SC; Calianno G; Chiricozzi A; Foti C
Ital J Dermatol Venerol; 2024 May; ():. PubMed ID: 38695596
[No Abstract] [Full Text] [Related]
17. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
18. Switching biologics in psoriasis - practical guidance and evidence to support.
Tsai YC; Tsai TF
Expert Rev Clin Pharmacol; 2020 May; 13(5):493-503. PubMed ID: 32394765
[TBL] [Abstract][Full Text] [Related]
19. Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective.
Zwicky P; Unger S; Becher B
J Exp Med; 2020 Jan; 217(1):. PubMed ID: 31727781
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Armstrong AW; Read C
JAMA; 2020 May; 323(19):1945-1960. PubMed ID: 32427307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
